Antiepileptic Drug Use

    Basic Details
    Date Posted
    Wednesday, November 20, 2013
    Status
    Complete
    Medical Product
    acetazolamide
    carbamazepine
    clobazam
    clonazepam
    diazepam
    ethosuxamide
    ezogabine
    felbamate
    gabapentin
    lacosamide
    lamotrigine
    levetiracetam
    lorazepam
    oxcarbazepine
    phenobarbital
    phenytoin
    pregabalin
    primidone
    rufinamide
    tiagabine
    topiramate
    valproic acid
    vigabatrin
    zonisamide
    Description

    Modular program-based one-time assessment of the use of antiepileptic drugs (AEDs), including acetazolamide, carbamazepine, clobazam, clonazepam, diazepam, ethosuxamide, ezogabine, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, rufinamide, tiagabine, topiramate, valproic acid, vigabatrin, and zonisamide.   Incident use was determined 1) with respect to an AED of interest, rather than all AEDs, and 2) with respect to all AEDs, rather than a specific AED of interest. Modular programs are adaptable standardized programs. Results were generated using Modular Program 2, version 3.1; click here for more information. Programs were executed in April 2011.

    If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@mini-sentinel.org.

    The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

    Additional Details
    FDA Center
    CDER
    Time Period
    2004 - 2012
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)